echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > GlaxoSmithKline/Vir monoclonal antibody sotrovimab is effective against key Omicron mutations

    GlaxoSmithKline/Vir monoclonal antibody sotrovimab is effective against key Omicron mutations

    • Last Update: 2022-01-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compile | newborn

    On December 2, GlaxoSmithKline (GSK) and Vir Biotech announced an update of a study on the preprinted website bioRxiv: Preclinical data showed that the monoclonal antibody sotrovimab targets the new Omicron SARS-CoV-2 variant ( B.


    (For details, see: The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 )

    These data were generated by pseudovirus testing of specific individual mutations found in Omicron


    Sotrovimab is a SARS-CoV-2 neutralizing monoclonal antibody that can bind to an epitope shared by SARS-CoV-2 and SARS-CoV-1 (the virus that causes SARS).


    Sotrovimab targets a conserved epitope of S protein that is unlikely to mutate over time


    Reference source: Preclinical data demonstrate sotrovimab retains activity against key Omicron mutations, new SARS-CoV-2 variant

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.